was founded in 2015 and is located in St. Valentin (Austria). The company focuses on the development, production and distribution of multiplex tests
for in-vitro diagnostics in clinical practice.
Multiplex diagnostics allow for the identification
in parallel of a variety of significant parameters (bacteria, fungi, resistance markers, etc.) in a single test, requiring only a minimal amount of sample material.
Cube Dx entirely new multiplex technology - the hybcell – is the only cylindrical microarray available anywhere – delivers speedy and reliableresults with minimal effort.
The hyborg – a completely automated device – processes the samples fully independently
and without any intervention by the user.
The Cube Dx assay is based on compact
sequencing and is designed to address especially those complex diagnostic challenges where fast
answers are essential.
support clinicians in their fight against sepsis - the most common causes of death, with someone dying every three seconds. The number of sepsis hospitalisations doubled in the US between 2000 and 2008. Sepsis represents a huge burden on healthcare providers, with about 1 in 10 patients in intensive care units suffering from sepsis. The cost of sepsis hospitalisations in the US exceeds $15 billion annually.
Cube Dx' early Pathogen Identification directly from whole blood and other sample matrices reduces
time to result to 3 hours after sample taking. Therefore targeted therapy can be chosen very quickly - even for patients already treated with antimicrobial agents.